Latest Esomeprazole Stories

Heartburn among asthma sufferers led some doctors to prescribe heartburn medication, but heartburn drugs do not help control asthma, U.S. researchers said. The study, conducted by the American Lung Association's Asthma Clinical Research Centers at 20 U.S. sites, the study demonstrated that participants who took esomeprazole, or Nexium, had as many asthma episodes as participants who were given an inactive pill, or placebo. This study goes against the idea that mild or silent acid reflux...

The surprising results of a recent study indicate that the decades long medical practice of prescribing heartburn medications to patients with asthma is ineffective.The new study found that the popular heartburn drug Nexium, also known as the purple pill, did not reduce asthma symptoms in patients who were not also suffering from heartburn.  An estimated 2.5 to 5 million suffer from a combination of asthma and gastroesophageal reflux, commonly referred to as heartburn.For at least the last...

--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezing and breathlessness were triggered in part by acid reflux. A new study conducted by the American Lung Association's Asthma Clinical Research Centers (ACRC) finds the longstanding practice of...

-Filing also includes age appropriate formulation of 2.5 mg and 5 mg strengths of NEXIUM for Delayed-Release Oral Suspension- WILMINGTON, Del., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients...

According to a new study, stent patients who take the blood thinner Plavix combined with heartburn drugs may face a greater risk of heart attack.Researchers concluded patients who took Plavix with popular prescription heartburn drugs, including AstraZeneca's Nexium, were more likely to be hospitalized for a heart attack, stroke, chest pain or a coronary artery bypass operation than those who took Plavix alone.A stent is a wire-mesh tube used to prop open arteries after they have been cleared...

POZEN Inc.'s (NASDAQ:POZN) PA32520 product candidate (enteric coated aspirin 325 mg with immediate release omeprazole 20 mg) may provide less upper gastrointestinal mucosal damage usually associated with higher doses of aspirin therapy, and may allow for treatment with higher doses of aspirin (up to 325 mg/daily) to maximize cardiovascular protection, according to new data presented today at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans, Louisiana. Findings...

POZEN Inc. (NASDAQ:POZN), announced today that it will release third quarter 2008 results on October 29, 2008, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. Eastern Time with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN's website at www.pozen.com and will be archived and available for replay. The third quarter 2008 earnings release will be accessible in the News section of POZEN's...

POZEN Inc. (NASDAQ: POZN), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that, as part of the FDA's on-going discussions with the Company and their review of both the Special Protocol Assessment (SPA) for PA32540 and the Statistical Analysis Plan (SAP) for PN 400, the FDA is conducting an internal review on the acceptability of using endoscopic gastric ulcers as a primary endpoint in clinical studies. The Company has been advised by the FDA that an...

POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will present at the UBS Life Sciences Conference on Tuesday, September 23, 2008 at 9:30 a.m. (ET) at the Grand Hyatt in New York. Dr. Plachetka's presentation will be webcast and archived on POZEN's home page at www.pozen.com. POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where...

POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. (ET) in New York City. POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the...